Ironwood Pharmaceuticals, Inc. - Class A Stock Prediction
AI-powered sentiment analysis and prediction trends for IRWD, updated each market day.
IRWD AI Sentiment
AI sees no strong directional signal for Ironwood Pharmaceuticals, Inc. - Class A stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Ironwood Pharmaceuticals, Inc. - Class A
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Sector
Exchange
Market Cap
$587,009,937
Cap Tier
Employees
100
Headquarters
BOSTON, MA
Listed Since
Feb. 3, 2010
Website
IRWD Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IRWD Volatility
Ironwood Pharmaceuticals, Inc. - Class A has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
